Crossmark

Epigenetic tuning of PD-1 expression improves exhausted T cell function and viral control

Crossref DOI link: https://doi.org/10.1038/s41590-024-01961-3

Published Online: 2024-09-17

Published Print: 2024-10

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Weiss, Sarah A. https://orcid.org/0000-0002-4155-0346
Huang, Amy Y. https://orcid.org/0000-0002-6646-6503
Fung, Megan E.

Martinez, Daniela

Chen, Alex C. Y. https://orcid.org/0000-0002-8358-5408
LaSalle, Thomas J.

Miller, Brian C.

Scharer, Christopher D. https://orcid.org/0000-0001-7716-8504
Hegde, Mudra

Nguyen, Thao H. https://orcid.org/0000-0002-2767-0528
Rowe, Jared H.

Osborn, Jossef F.

Patterson, Dillon G.

Sifnugel, Natalia

Mei-An Nolan, C. https://orcid.org/0000-0002-8109-7339
Davidson, Richard A.

Schwartz, Marc A. https://orcid.org/0000-0003-3869-0150
Bally, Alexander P. R.

Neeld, Dennis K.

LaFleur, Martin W. https://orcid.org/0000-0002-5017-774X
Boss, Jeremy M. https://orcid.org/0000-0002-2432-1840
Doench, John G. https://orcid.org/0000-0002-3707-9889
Nicholas Haining, W. https://orcid.org/0000-0001-7871-3762
Sharpe, Arlene H. https://orcid.org/0000-0002-9736-2109
Sen, Debattama R. https://orcid.org/0000-0002-0947-8284
Funding

Funding for this research was provided by:

U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (DP2 AI176139, U19 AI082630, P01 AI052699, R01 AI113021, R01 AI113021, R01 AI113021, R01 AI113021)

Melanoma Research Alliance

V Foundation for Cancer Research

U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (T32 GM007753, T32 GM144273, T32 GM144273)

U.S. Department of Health & Human Services | NIH | National Cancer Institute (T32 CA207021, T32 CA921643, K08 CA248960)
License Information

Text and Data Mining valid from 2024-09-17

Version of Record valid from 2024-09-17
More Information

Article History

Received: 29 November 2022

Accepted: 8 August 2024

First Online: 17 September 2024

Competing interests

: A.H.S. has patents/pending royalties on the PD-1 pathway from Roche and Novartis and has research funding from IOME, AbbVie, Taiwan Bio and Calico unrelated to the submitted work. A.H.S. serves on advisory boards for Elpiscience, Monopteros, Alixia, IOME, Corner Therapeutics, BioEntre, GlaxoSmithKline, Amgen and Janssen and is also on scientific advisory boards for the Massachusetts General Cancer Center, Program in Cellular and Molecular Medicine at Boston Children’s Hospital, the Human Oncology and Pathogenesis Program at Memorial Sloan Kettering Cancer Center, Perlmutter Cancer Center at New York University, the Gladstone Institutes and the Bloomberg-Kimmel Institute for Cancer Immunotherapy at Johns Hopkins. A.H.S. is an academic editor for the <i>Journal of Experimental Medicine</i>. W.N.H. and D.R.S. have a patent application on T cell exhaustion-specific enhancers held by the Dana-Farber Cancer Institute. W.N.H. is a cofounder, employee of and equity holder in Arsenal Biosciences. W.N.H. holds equity in Tango Therapeutics and Arsenal Biosciences. B.C.M. has consulted for Cellarity, LifeOmic and Telix Pharmaceuticals. The remaining authors declare no competing interests.

Document is current

Any future updates will be listed below